Improvement of 11 patients with nail psoriasis with apremilast: Results of an investigator-initiated open-label study

J Am Acad Dermatol. 2020 Dec;83(6):1830-1832. doi: 10.1016/j.jaad.2020.05.087. Epub 2020 May 22.

Authors

Allen S W Oak¹, Hoang Ho-Pham¹, Boni E Elewski²

Affiliations

¹ Department of Dermatology, The University of Alabama at Birmingham, Birmingham, Alabama.
² Department of Dermatology, The University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: beelewski@gmail.com.

PMID: 32446819
DOI: 10.1016/j.jaad.2020.05.087

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Administration, Oral
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Nail Diseases / diagnosis
Nail Diseases / drug therapy*
Phosphodiesterase 4 Inhibitors / administration & dosage*
Phosphodiesterase 4 Inhibitors / adverse effects
Psoriasis / diagnosis
Psoriasis / drug therapy*
Severity of Illness Index
Thalidomide / administration & dosage
Thalidomide / adverse effects
Thalidomide / analogs & derivatives*
Treatment Outcome

Substances

Phosphodiesterase 4 Inhibitors
Thalidomide
apremilast